Cell signalling
Thursday - Friday 29 - 30 November 2007
Venue: The Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE
A joint meeting with the British Association of Cancer Research
This meeting will bring together scientists and clinicians who are either working on or are interested in learning about cell signalling in cancer therapeutics.
Key speakers from across North America and Europe who work in both university and pharmaceutical backgrounds will provide the latest information in this hot area of new science.
Our two day international meeting will have sessions focused on receptors, mTOR / S6 kinase, BRaf/MEK/Erk, JAK/STAT, PI3K/apoptosis and Src/migration signalling.
Each session will have a biology component followed by a clinical translation talk.
Registration Details:
RSM/BACR Member: £120
RSM Trainee: £100
RSM/BACR Student member: £80
RSM/BACR Non member: £240
Trainee/Nurse/AHP: £150
Student: £100
Dinner: £50
Meeting ref: OG-E10-2
Thursday 29 November 2007 |
|
8.30 am |
Registration, tea and coffee |
|
Receptors |
|
| Chair: Sue Burchill | |
9.00 am |
Targeting VEGF and VEGFR |
| Sue Burchill (Leeds, UK) | |
9.30 am |
EGFR and differences between antagonists |
| John Kuriyan (Berkeley, US) | |
10.00 am |
EGFR antagonists - response in the clinic |
| Frances Shepherd (Toronto, Canada) | |
10.30 am |
Tea and coffee break |
|
S6Ks + mTOR |
|
| Chair: Michael Seckl | |
11.00 am |
mTOR/S6Ks |
| George Thomas (Cincinnati, US) | |
11.30 pm |
mTOR signalling and oncogenesis |
| John Blenis (Boston, US) | |
12.00 pm |
mTOR/S6Ks as clinical targets |
| Michael Seckl (London, UK) | |
12.30 pm |
Lunch |
1.30 pm |
4 (15 minute talks) to be selected from submitted abstracts |
2.30 pm |
Poster Session with Tea and Coffee |
|
JAK/STAT |
|
| Chair: Ana Costa-Pereira | |
3.30 pm |
JAK/STAT signalling: canonical and novel signalling pathways |
| Ana Costa-Pereira (London, UK) | |
4.00 pm |
STAT1: tumour suppressor oncogene? |
| Veronica Sexl (Vienna, Austria) | |
4.30 pm |
The role of STAT3 in oncogenesis |
| Heike Hermanns (Aachen, Germany) | |
5.00 pm |
JAK2 mutations and human haematological malignancies |
| Tony Green (Cambridge, UK) | |
5.30 pm |
Drinks Reception |
7.00 pm |
Conference dinner (for those who have pre-booked) |
Friday 30 November 2007 |
|
8.30 am |
Registration, tea and coffee |
|
RAF/MEK |
|
| Chair: Olivier Pardo | |
9.00 am |
MAPK network topology shapes Erk response in PC-12 cell fate decision |
| Philippe Bastiaens (Dortmund, Germany) | |
9.30 am |
B-Raf biology - novel antagonists |
| Richard Marais (London, UK) | |
10.00 am |
Role of translational biology in MEK inhibitor development |
| Judith Sebolt-Leopold (Ann Arbor, US) | |
10.30 am |
Tea and coffee break |
|
Apoptosis |
|
| Chair: Julian Downward | |
11.00 am |
PI 3-kinase signalling pathways in cancer |
| Julian Downward (London, UK) | |
11.30 am |
Bcl-2 family inhibitors for the treatment of cancer |
| Stephen Fesik ( Abbott Park, US) | |
12.00 pm |
PI3 kinase and Hsp90 inhibitors |
| Paul Workman (The Institute of Cancer Research, Sutton, UK) | |
12.30 pm |
P53 and novel therapies |
| Karen Vousdon (Glasgow, UK) | |
1.00 pm |
Lunch |
|
Migration |
|
| Chair: Margaret Frame | |
2.00 pm |
Src biology - a target for new cancer therapies |
| Margaret Frame (Glasgow, UK) | |
2.30 pm |
Rho GTPases, actomyosin contractility and cell migration |
| Chris Marshall ( London, UK) | |
3.00 pm |
Title (to be confirmed) |
| George Demetri (Boston, US) | |
3.30 pm |
Key note Lecture - A systems biology approach to drug development and implementation |
| Gordon B Mills (Houston, US) | |
4.00 pm |
Close of meeting, tea and coffee served |